Membrane extraction techniques in bioanalysis J. Å. JönssonL. Mathiasson State-of-the-Art Pages: S8 - S11
Solid-phase micro-extraction in bioanalysis, exemplified by lidocaine determination G. J. de JongE. H. M. Koster State-of-the-Art Pages: S12 - S13
Further studies on the MEKC and MEEKC of UV-Absorbing compounds in human urine D. PerreffV. MelinL. Alfazema State-of-the-Art Pages: S14 - S18
Application and elution conditions for the selective elution of analytes from molecular imprinted polymers after extraction from aqueous samples: Application to β-blockers P. MartinI. D. WilsonG. R. Jones State-of-the-Art Pages: S19 - S23
Capillary electrochromatography + molecular imprinting = drug analysis? S. NilssonL. SchweitzL. I. Andersson State-of-the-Art Pages: S24 - S24
On-line coupling of SPE with MS for analysis of biosamples, exemplified by the determination of clenbuterol in urine G. J. de JongM. JeronimusK. Ensing State-of-the-Art Pages: S25 - S25
Turbulent flow chromatography combined with tandem mass spectrometry for directly injecting raw plasma samples derived from pharmacokinetic studies D. ZimmerV. PickardC. Müller State-of-the-Art Pages: S26 - S27
Investigation of a range of stationary phases for the separation of model drugs by HPLC using superheated water as the mobile phase I. D. Wilson State-of-the-Art Pages: S28 - S34
The application ofin vitro models for production of metabolites: Isolation and characterisation of hydroxysecobarbital D. MarshallM. RobinsonE. Houghton State-of-the-Art Pages: S35 - S38
Determination of unlabeled and14C-radiolabeled drug candidates in biological fluids using LC-MS-MS—Issues and challenges B. K. MatuszewskiC. Chavez-EngM. L. Constanzer Assay Acceptability and Strategies Pages: S39 - S45
Application of LC-SIM-MS in drug assay development P. HeizmannR. GösslR. Herissé Assay Acceptability and Strategies Pages: S46 - S48
One method for all species: Two case studies L. BentleyJ. HardenH. M. Hill Assay Acceptability and Strategies Pages: S49 - S52
The validation of bioanalytical methods in unusual or multiple matrices during human drug development M. W. H. Clark Assay Acceptability and Strategies Pages: S53 - S54
Use of non-ambient temperatures in separatory runs E. Reid Assay Acceptability and Strategies Pages: S55 - S56
Unorthodox temperature conditions: Opinions and supplementary observations from bioanalytical forum participants U. A. Th. BrinkmanH. M. HillE. Reid Assay Acceptability and Strategies Pages: S57 - S59
ESI-MS response characteristics of a synthetic peptide D. R. ZookH. Forsmo-BruceS. Briem Assay Acceptability and Strategies Pages: S60 - S64
Bioanalytical methods validation: A critique of the proposed FDA guidance H. M. Hill Assay Acceptability and Strategies Pages: S65 - S69
Bioanalytical support to a discovery program J. M. LongS. CavanusM. Gallina Assay Acceptability and Strategies Pages: S70 - S71
Cross validation in bioanalysis: Why, when and how? D. C. MuirheadT. S. Smart Assay Acceptability and Strategies Pages: S72 - S75
Are commercial immunoassay kits satisfactory for measuring pharmacodynamic and surrogate endpoints? I. T. James Assay Acceptability and Strategies Pages: 576 - 577
High performance liquid chromatographic method for the determination of homocysteine in human plasma using a water-soluble phosphine reducing agent and fluorogenic derivatization M. C. WhittleJ. F. StobaughO. S. Wong Particular Analytes Pages: S78 - S82
Fluorescence determination of sulphobutylether-β-cyclodextrin sodium in human plasma and urine by size-exclusion chromatography with inclusion complex formation M. A. J. BaylissR. GageR. F. Venn Particular Analytes Pages: S83 - S86
Analysis of CP-122,288 at femto-molar levels from human plasma using solid-supported extraction and HPLC column switching K. C. SaundersR. F. VennJ. A. Fane Particular Analytes Pages: S87 - S91
Rapid determination of the anti-cancer drug Melphalan (AlkeranTM) in human serum and plasma by automated solid phase extraction and liquid chromatography tandem mass spectrometry I. D. DaviesJ. P. AllansonR. C. Causon Particular Analytes Pages: S92 - S97
The rapid determination of tobramycin in microlitre quantities of human tear fluid using LC-MS-MS L. W. ReesA. D. MunnP. R. Robinson Particular Analytes Pages: S98 - S100
Analysis of pharmacologically active cannabinoids by GC-MS M. V. DoigR. Andela Particular Analytes Pages: S101 - S102
Thirteen years of quetiapine (‘Seroquel’) bioanalysis P. C. Davis Particular Analytes Pages: S103 - S103
Validation of an inductively coupled plasma (ICP) MS method as applied to measure oxaliplatin-derived platinum in pharmacokinetic studies J. G. MorrisonP. WhiteD. Greenslade Particular Analytes Pages: S104 - S104
Determination of gatifloxacin in human serum and urine by HPLC K. BornerH. HartwigH. Lode Particular Analytes Pages: S105 - S107
Determination of zanamavir, a viral neuramidase inhibitor, in human serum by LC-MS-MS G. D. AllenS. T. Brookes Particular Analytes Pages: S108 - S108
Determination of the retinoic acid metabolism blocking agent R115866 in human plasma by gas chromatography-high resolution mass spectrometry T. VerhaegheL. Diels Particular Analytes Pages: S109 - S112
Development of an analytical methodology from toxicokinetic to clinical studies for the anti-migraine drug frovatriptan L. LaugherR. BriggsT. A. G. Noctor Particular Analytes Pages: S113 - S119
